Archive for the ‘ pharma ’ Category
According to an editorial in The New York Times, “A prime driver of our escalating health care costs is the advance of medical technology …” Indeed. The driver of the Gray Lady’s oration is the decision by Medicare to pay for both Provenge (advanced prostate cancer) and Avastin (for breast cancer – even if the [...]
Never express yourself more clearly than you are able to think. –Niels Bohr Think regulatory headaches about Facebook is a hot topic? Here are some communications issues that make social media guidance pale in comparison. Yesterday Eli Lilly, Johnson & Johnson, Novartis, Novo Nordisk, Pfizer and sanofi-aventis will file a Citizen Petition with the U.S. [...]
I’ve just returned from the big BIO bash, where I was honored to moderate the panel discussion, “Lessons From In-Licensing Partnership: Biotech Company Partners with Global Pharma to Deliver Cutting-Edge Follow-On Biologics.” I was joined on the podium by joined by Arun Chandavarkar, chief operating officer of Biocon Ltd.; Stephen Hoge, principal at McKinsey & [...]
Ah, the brief summary. Inside the FDA many joke that it is like the Holy Roman Empire – neither brief nor a summary. And if you want to throw in “fair balance and adequate provision,” well, go right ahead. Same issue – too much information equals not enough comprehension. It’s not a new [...]
The use of social media by regulated industry is faltering because of fear, timidity, and misunderstanding. I’d like to make five main points that are often overlooked or misconstrued when we discuss social media in the context of regulated speech: 1. There is a difference between online advertising and social media When the FDA sent [...]
I’ve just returned from deep in the heart of America’s Medicine Chest (Princeton, NJ), where I was proud to chair the Social Media for Pharma conference. The conversation included when FDA guidelines might be released, and if it even matters; the appropriate balance between sales and education; the role of the digitally empowered health [...]
“Newspeak,” as Orwellian cognoscenti know, is the official language of Big Brother, designed “not to extend but to diminish the range of thought.” Its goal was to “make all other modes of thought impossible.” Which brings us from the nightmare fantasy of 1984 to the health care debate of 2011 and the concept of “cost-think.” [...]
At the end of the day, nearly all marketing efforts are focused on two primary goals: creating new customers, and then, retaining them. While it can be argued that for its first century marketeering was primary focused on the first part of the equation, it can equally be argued that the next 100 years will [...]
The future of health can be summed up in one word: data. Or more specifically, the combination of of health data sets that had never been connected before. In a fascinating panel titled, “Panel Health Data Everywhere: Not a Drop to Link,” panelists discussed how this new mashup of health data is creating new innovative [...]